Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Patient access schemes

Plans to expand NHS medicine access scheme

Changes are being made to the Accelerated Access Collaborative to allow the NHS to use ground-breaking medical products sooner.

The government is promising quicker access to new breakthrough medicines as part of improvements to the Accelerated Access Collaborative (AAC).

The existing AAC was established in 2018 to speed up the process to allow potentially ground-breaking medicines and products into the NHS.

Under the new changes, the AAC will become the umbrella organisation for UK health innovation, which will support manufacturers and others overcoming barriers for their innovative products and become the ‘front door’ for innovators looking to get their products funded by the NHS.

A new NHS unit has been established to support the AAC, which will now create a single point of call for innovators keen to get their products into the NHS; establishing a “global leading” testing infrastructure is also planned as part of the changes.

The changes were announced on 2 May 2019 at the annual conference of the Association of the British Pharmaceutical Industry, where Mike Thompson, chief executive officer at the association, said the development would change the lives of patients in the UK.

“It sends a clear message that the UK intends to build an innovation-led economy alongside a more productive, innovation-ready NHS,” he said.

Health minister Baroness Blackwood also told the conference that the goal was to ensure NHS patients would be the first in the world to get access to life-saving treatments, adding that “We also need to ensure that we stop using products that are no longer effective”.

Blackwood said that in order to ensure “regulatory flexibility” she had asked the National Institute for Health and Care Excellence to look at its technology appraisals and highly specialised technology evaluation methods.

Since the AAC was established, it has selected and supported 12 ‘rapid uptake products’ for use in the NHS, including an early blood test for pre-eclampsia during pregnancy.

The Department for Health and Social Care said the products have the potential to improve the lives of around 500,000 patients and save the NHS up to £30m.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2019.20206502

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.